Sorry for interrupting your 3 vs. 4 discussions.
Post# of 154119
(Total Views: 490)
Posted On: 02/02/2020 10:29:03 AM
Sorry for interrupting your 3 vs. 4 discussions.
I just can't help it with what I see.
Thought to share my vision with you fellas. This comes from company's approach to FDA
Nader explicitly said this works on 100% of test population. He was trying to said we are confident that it works on 100% of metastatic cancer patients and thus we are filing for Type C and phase 4 but due to limitations they have on jutms telling and not what they are confident on, he couldn't say it explicitly.
As you know we where $1 last day of Dec. and might know my projection for end of Q1 (still 2 months away) was $2.50.
After Fridays video I know my expectation for Q2. Whether we hit or pass Q1s projection.
I can see this being somewhere in the range of low end of $5 and high of $12.50 depending on FDA's responsiveness to cancer.
So, for end of Q2 I'm setting my target to $7.50 with a outperform of $12.5.
I couldn't keep the numbers to myself.
Please carry on the 3 and 4 thing.
I just can't help it with what I see.
Thought to share my vision with you fellas. This comes from company's approach to FDA
Nader explicitly said this works on 100% of test population. He was trying to said we are confident that it works on 100% of metastatic cancer patients and thus we are filing for Type C and phase 4 but due to limitations they have on jutms telling and not what they are confident on, he couldn't say it explicitly.
As you know we where $1 last day of Dec. and might know my projection for end of Q1 (still 2 months away) was $2.50.
After Fridays video I know my expectation for Q2. Whether we hit or pass Q1s projection.
I can see this being somewhere in the range of low end of $5 and high of $12.50 depending on FDA's responsiveness to cancer.
So, for end of Q2 I'm setting my target to $7.50 with a outperform of $12.5.
I couldn't keep the numbers to myself.
Please carry on the 3 and 4 thing.
(5)
(0)